Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.
Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions
Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.
Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study
Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.